What is Immunis?
Immunis operates at the intersection of stem cell biology and immunology, focusing on the development of therapeutic interventions for age-related and disease-driven immune deficits. By utilizing a novel method to cultivate human stem cells, the company produces highly pure populations of cells that secrete essential factors for immune modulation and health. This technology aims to replace the physiological factors that naturally diminish with age, offering a balanced, all-human solution for systemic health. Currently, the company is advancing its lead candidate, STEM, through a Phase 1/2a clinical trial specifically targeting muscle atrophy, a condition that affects the aging population globally. By addressing the root causes of immune senescence, Immunis is carving out a unique market position in the high-growth longevity therapeutics landscape.
How much funding has Immunis raised?
Immunis has raised a total of $35M across 2 funding rounds:
Series A
$10M
Series A
$25M
Series A (2022): $10M with participation from Remiges Ventures
Series A (2025): $25M led by LifeSpan Vision Ventures and BOLD Capital Partners
Key Investors in Immunis
Remiges Ventures
Remiges Ventures is a venture capital firm focused on incubating and investing in innovative drug discovery initiatives, providing strategic guidance to biotechnology firms.
LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking investment firm specializing in the aging and longevity space, supporting therapies that extend healthspan.
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world through disruptive science.
What's next for Immunis?
With the recent infusion of capital, Immunis is well-positioned to accelerate its clinical development roadmap. The primary focus will be the successful execution of its ongoing Phase 1/2a study, which serves as a critical proof-of-concept for the efficacy of its immune-modulating factors in human subjects. Strategic priorities include scaling manufacturing capabilities to meet clinical trial demands and potentially expanding the application of its technology to other age-related pathologies. As the company matures, it will likely seek further partnerships with pharmaceutical entities to streamline the regulatory pathway and commercialization of its regenerative therapies, ensuring that its innovative approach to immune health reaches the broader market effectively.
See full Immunis company page
